Baker-Glenn
Charles Baker-Glenn, Puckeridge GB
Patent application number | Description | Published |
---|---|---|
20110301141 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS - Compounds of the formula I: | 12-08-2011 |
Charles Baker-Glenn, Essex GB
Patent application number | Description | Published |
---|---|---|
20120071460 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS - The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases, wherein R | 03-22-2012 |
20130116289 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE(SIP)RECEPTORS - The present invention provides compounds of Formula (I), as selective S1P1 inhibitors, as well as their use for treating multiple sclerosis and other diseases. | 05-09-2013 |
20140155373 | NOVEL COMPOUNDS - Compounds of formula (I) described herein are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction. | 06-05-2014 |
20140155427 | NOVEL COMPOUNDS - Compounds of formula (I) described herein are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction. | 06-05-2014 |
20140155428 | NOVEL COMPOUNDS - Compounds of formula (I) defined herein are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract characterized by airway obstruction. | 06-05-2014 |
Charles Baker-Glenn, St. Neots GB
Patent application number | Description | Published |
---|---|---|
20120157427 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS - Compounds of the formula I: | 06-21-2012 |
20130096102 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS - Compounds of the formula I: | 04-18-2013 |
20130157999 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS - Specific Compounds of formula I: | 06-20-2013 |
20130158006 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS - Compounds of the formula I: | 06-20-2013 |
20130158032 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS - Compounds of the formula I: | 06-20-2013 |
20130158057 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS - Compounds of the formula I: | 06-20-2013 |
20150051201 | BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS - Compounds of formula I: | 02-19-2015 |
20150051238 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS - Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease. | 02-19-2015 |
Charles Baker-Glenn, Saffron Walden GB
Patent application number | Description | Published |
---|---|---|
20150158857 | BENZHYDRYL DERIVATIVES - Compounds having a benzhydryl structure represented by formula (I) described herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for treating diseases of the respiratory tract. | 06-11-2015 |
20150158858 | HETEROARYL DERIVATIVES - Compounds of formula (I) described herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction. | 06-11-2015 |
Charles Anthony Graham Baker-Glenn, Saffron Walden GB
Patent application number | Description | Published |
---|---|---|
20140329822 | N-PIPERIDIN-4-YL DERIVATIVES - The invention relates to a N-piperidin-4-yl derivative having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same and to the use of said N-piperidin-4-yl derivatives for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, or for the treatment of uterine fibroids or other menstrual-related disorders. | 11-06-2014 |